Key result
The no-reflow phenomenon occurs in 30% or more of patients with acute coronary syndrome undergoing reperfusion therapy, significantly increasing the risk of complications and death.
Population
Patients with acute coronary syndrome undergoing thrombolysis, percutaneous coronary intervention, or…
Design
Review
Authors
Loading...
No-reflow in ACS reperfusion signals high complication risk; leaves open optimal prevention strategies for prospective trials.
The no-reflow phenomenon is a critical complication of reperfusion therapy in ACS, necessitating targeted diagnostic approaches (TIMI, MBG) and specific pharmacological or mechanical interventions.
Iskhakov et al. (2015) conducted a review in Acute coronary syndrome, no-reflow phenomenon. Reperfusion therapy and treatments for no-reflow (e.g., adenosine, verapamil, abciximab) was evaluated. The no-reflow phenomenon occurs in 30% or more of patients with acute coronary syndrome undergoing reperfusion therapy, significantly increasing the risk of complications and death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: